Seamus Fernandez
Stock Analyst at Guggenheim
(3.80)
# 752
Out of 4,711 analysts
91
Total ratings
53.45%
Success rate
8.46%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Reiterates: Buy | n/a | $47.71 | - | 6 | Dec 12, 2024 | |
| CDTX Cidara Therapeutics | Initiates: Buy | $33 | $23.22 | +42.12% | 1 | Nov 8, 2024 | |
| MRK Merck & Co. | Maintains: Buy | $137 → $130 | $98.05 | +32.59% | 13 | Nov 6, 2024 | |
| GSK GSK | Downgrades: Neutral | n/a | $33.60 | - | 2 | Oct 31, 2024 | |
| RYTM Rhythm Pharmaceuticals | Initiates: Buy | $70 | $56.12 | +24.73% | 1 | Oct 21, 2024 | |
| TENX Tenax Therapeutics | Initiates: Buy | $16 | $5.61 | +185.20% | 1 | Oct 14, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $44 | $20.36 | +116.11% | 1 | Oct 8, 2024 | |
| LLY Eli Lilly | Maintains: Buy | $884 → $1,030 | $767.76 | +34.16% | 14 | Aug 16, 2024 | |
| RVNC Revance Therapeutics | Downgrades: Neutral | n/a | $3.09 | - | 1 | Aug 12, 2024 | |
| HLVX HilleVax | Downgrades: Neutral | n/a | $1.86 | - | 3 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.25 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $56 → $55 | $5.74 | +858.19% | 1 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $15.48 | - | 2 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $12.34 | +159.32% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $65 | $86.53 | -24.88% | 2 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $27.90 | +79.21% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $57.33 | - | 12 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $85.00 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $97.11 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.68 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $27 | $83.45 | -67.65% | 4 | Nov 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $2.72 | +1,885.29% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $25.14 | +79.00% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $65.35 | -41.85% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $26.36 | +44.16% | 3 | Jan 31, 2018 |
Apogee Therapeutics
Dec 12, 2024
Reiterates: Buy
Price Target: n/a
Current: $47.71
Upside: -
Cidara Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $33
Current: $23.22
Upside: +42.12%
Merck & Co.
Nov 6, 2024
Maintains: Buy
Price Target: $137 → $130
Current: $98.05
Upside: +32.59%
GSK
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $33.60
Upside: -
Rhythm Pharmaceuticals
Oct 21, 2024
Initiates: Buy
Price Target: $70
Current: $56.12
Upside: +24.73%
Tenax Therapeutics
Oct 14, 2024
Initiates: Buy
Price Target: $16
Current: $5.61
Upside: +185.20%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $44
Current: $20.36
Upside: +116.11%
Eli Lilly
Aug 16, 2024
Maintains: Buy
Price Target: $884 → $1,030
Current: $767.76
Upside: +34.16%
Revance Therapeutics
Aug 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.09
Upside: -
HilleVax
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.86
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $8.25
Upside: -
Aug 15, 2023
Maintains: Buy
Price Target: $56 → $55
Current: $5.74
Upside: +858.19%
Jul 14, 2023
Maintains: Buy
Price Target: n/a
Current: $15.48
Upside: -
Mar 7, 2023
Initiates: Buy
Price Target: $32
Current: $12.34
Upside: +159.32%
Feb 28, 2023
Maintains: Buy
Price Target: $66 → $65
Current: $86.53
Upside: -24.88%
Feb 28, 2023
Initiates: Buy
Price Target: $50
Current: $27.90
Upside: +79.21%
Oct 10, 2022
Downgrades: Neutral
Price Target: n/a
Current: $57.33
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $85.00
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $97.11
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $4.68
Upside: -
Nov 15, 2018
Initiates: Outperform
Price Target: $27
Current: $83.45
Upside: -67.65%
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $2.72
Upside: +1,885.29%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $25.14
Upside: +79.00%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $65.35
Upside: -41.85%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $26.36
Upside: +44.16%